Some of the soundbite health care policy proposals that candidates bring up for short-term political impact could in practice ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Itovebi — also known as inavolisib — is designed to be given with drugs from Pfizer Inc. and AstraZeneca plc to treat adults ...

Genentech, a member of the Roche (RHHBY), announced topline one-year results from the open-label, single-arm Phase IV ...

Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Data from the Rainbowfish trial was presented at the World Muscle Society (WMS) Congress 2024 in Prague, Czech Republic.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...